Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy
European Journal of Cancer2004Vol. 41(3), pp. 453–460
Citations Over TimeTop 10% of 2004 papers
Ricardo Hitt, Eva Ciruelos, María L. Amador, Amparo Benito, José Javier Sánchez, Claudio Ballestı́n, H. Cortés-Funes
Related Papers
- → The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin(2001)86 cited
- Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.(1994)
- → Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma(2000)10 cited
- → Comparative antitumour activity of cisplatin and two new cisplatin‐analogues JM8 and JM9 in human testicular carcinoma xenografts(1987)3 cited
- The Relationship between Expression of 1-Cys Peroxiredoxin and Resistance to Cisplatin in Epithelial Ovarian Cancer Cell Lines.(2006)